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Commentary
Ramsden and colleagues provide an updated meta-analysis of the effects of dietary LA for secondary prevention of CHD and death, adding data from the SDHS, which was conducted from 1966 to 1973. A central question focuses on the CV effects of replacing saturated fat in the diet with n-6 ("omega-6") PUFAs, primarily in the form of LA, compared with replacing saturated fat with a combination of n-6 and n-3 ("omega-3") PUFAs. The authors conclude from their updated meta-analysis that n-6 PUFAs are associated with no indication of CHD benefit and an increased risk for CHD and all-cause mortality when they are substituted for saturated fat without n-3 PUFAs, although the effects were not statistically significant. A proposed mechanism that may contribute to these effects is increased susceptibility of low-density lipoprotein (LDL) that is enriched with n-6 LA to oxidation; increased LDL oxidation may contribute to CV disease.
In contrast, a 2009 advisory from the American Heart Association (1) concludes that n-6 PUFAs are beneficial for CHD prevention. The current meta-analysis separates studies with only n-6 supplementation but is limited by small sample sizes and wide confidence intervals, crossing 1.0 in 2 of 3 contributing RCTs. Only the newly added SDHS data show a significant increase in CHD risk in the group assigned to increased n-6 PUFAs through use of safflower oil products.
Although the updated meta-analysis raises questions about interventions aimed specifically at increasing intake of n-6 PUFAs alone, it is not compelling enough to merit a change in advice by clinicians about intake of n-6 fatty acids. The ideal dietary pattern of fat intake for minimizing CHD risk and optimizing human health remains uncertain and may vary according to underlying genetic factors (2). Future research should focus on optimal dietary patterns, including PUFA intake, and interaction with genetics. 
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Question
Does increasing dietary n-6 polyunsaturated fatty acids (PUFAs) compared with dietary saturated fatty acids (SFAs) reduce risk for coronary heart disease (CHD) mortality or cardiovascular (CV) mortality?
Review scope
The current meta-analysis updated a previous analysis* by incorporating additional data on cause of death from the Sydney Diet Heart Study (SDHS), done between 1966 and 1973. Included studies evaluated dietary interventions that increased PUFAs compared with SFAs, provided sufficient information to classify PUFA interventions as n-6 specific (linoleic acid [LA]-selective) or mixed n-3/n-6, {and had similar CHD risk factors in each study group}*. Cluster randomized trials were excluded. Outcomes were all-cause, CHD, and CV mortality.
Review methods
{MEDLINE, Web of Science, and 2 previous meta-analyses}* were searched for randomized controlled trials (RCTs). {Investi-gators were contacted}*. 7 RCTs (8 comparisons, n = 11 275, 59% men, follow-up range 2 to 8 y) met selection criteria and were included in the analyses: 3 used LA-selective PUFA interventions, and 4 used mixed n-3/n-6 PUFA interventions.
Main results
Meta-analysis showed that dietary n-6 PUFAs did not reduce all-cause, CV, or CHD mortality compared with dietary SFAs (Table) . Results by PUFA type are shown in the Table.
Conclusions
Dietary n-6 specific or mixed n-3/n-6 polyunsaturated fatty acids do not reduce all-cause or coronary heart disease mortality compared with dietary saturated fatty acids. Mixed n-3/n-6 polyunsaturated fatty acids reduce cardiovascular mortality. Br J Nutr. 2010; 104:1586-600. 
